Health-care companies rose, but not by as much as the broad market, as traders rotated out of defensive sectors into cyclical areas amid economic and debt-ceiling optimism. Biogen shares gained. | June 1, 2023
Wide coverage of Alzheimer s drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University. | May 11, 2023
Biogen has published its 2022 ESG Report, which supports Biogen s business goals by sharing our corporate responsibility story, disclosing key environmental, social, and governance . | May 1, 2023
Nature Medicine has published a manuscript detailing promising results from Biogen s multiple ascending dose Phase 1b trial, which evaluated the safety, pharmacokinetics and target. | April 28, 2023